QTRX Quanterix Corp
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1503274 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.8%
TTM net income YoY-16.2%
TTM EPS YoY0.0%
Revenue 3-yr CAGR8.3%
Net income 3-yr CAGR—
Margins
Gross margin41.7%
Operating margin-93.2%
Net margin-75.0%
FCF margin-37.8%
EBITDA margin-76.7%
Returns
ROE-41.7%
ROA-29.9%
ROIC (approx.)-47.4%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $138.90M | $137.42M |
| Cost of revenue | $73.94M | $54.32M |
| Gross profit | $64.96M | $83.10M |
| R&D expense | $35.92M | $31.08M |
| SG&A expense | $138.01M | $101.62M |
| Operating income | -$125.54M | -$52.62M |
| Pretax income | -$112.27M | -$38.10M |
| Income tax | -$5.12M | $434,000 |
| Net income | -$107.15M | -$38.53M |
| EBITDA | -$109.70M | -$46.15M |
| EPS (basic) | -2.51 | -1.00 |
| EPS (diluted) | -2.51 | -1.00 |
| Weighted avg. shares (diluted) | 42.64M | 38.37M |
| Banking | ||
| Net interest income | $8.57M | $14.65M |
| Provision for credit losses | $1.47M | $712,000 |
| Balance sheet | ||
| Cash & equivalents | $29.84M | $59.32M |
| Short-term investments | $88.39M | $232.41M |
| Receivables | $29.97M | $32.14M |
| Inventory | $54.76M | $32.77M |
| Current assets | $212.26M | $363.59M |
| PP&E, net | $23.67M | $17.15M |
| Goodwill | $26.38M | $0 |
| Intangibles | $131.79M | $4.03M |
| Total assets | $418.77M | $406.53M |
| Current liabilities | $74.76M | $42.01M |
| Total liabilities | $123.04M | $76.50M |
| Shareholders' equity | $295.73M | $330.04M |
| Shares outstanding | 46.74M | 38.57M |
| Cash flow statement | ||
| Operating cash flow | -$77.24M | -$35.16M |
| Capital expenditure | $2.61M | $3.37M |
| Free cash flow | -$79.85M | -$38.53M |
| Investing cash flow | $50.23M | -$82.27M |
| Financing cash flow | -$708,000 | $456,000 |
| Depreciation & amortization | $15.84M | $6.46M |
| Stock-based compensation | $20.72M | $19.99M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.